Human T Cell Responses Reveal New Pathways for Tuberculosis Vaccine Development

UH Research & Education Institute

Stephen Carpenter, MD, PhD

Tuberculosis remains a leading cause of death worldwide, yet vaccine development has been hindered by an incomplete understanding of what constitutes protective immunity. Dr. Stephen Carpenter’s recent research provides critical new insight into how the immune system:

• Recognizes and responds to infected cells
• Identifies T cell effector functions and antigen targets essential for protection
• Clarifies the mechanisms underlying effective immunity

As a result, this study offers an important foundation for designing more precise and effective next-generation TB vaccines.

Toward More Effective TB Vaccines

A study led by Stephen M. Carpenter, MD, PhD,in the Division of Infectious Diseases at University Hospitals and Assistant Professor at Case Western Reserve University School of Medicine addresses this gap by demonstrating that most human CD4+ T cells from individuals with latent Mycobacterium tuberculosis (Mtb) infection can directly recognize Mtb–infected macrophages, a critical step in immune control. The research further identifies the antigen specificity and effector functions of T cells that: (1) recognize infected macrophages, and (2) are associated with resistance to developing active TB, providing a clearer framework for next-generation vaccine design.

Defining Human Immune Responses to Tuberculosis

Published in The Journal of Experimental Medicine (2025), the study focuses on CD4+ T cells, a central component of host defense against Mtb. While prior animal studies in TB suggested that many Mtb-specific T cells in the lungs fail to recognize infected macrophages, whether this limitation applies to human immunity has remained unclear.

To address this, the investigators developed an ex vivo system using primary immune cells from individuals with stable latent Mtb infection. By infecting autologous macrophages with virulent Mtb and evaluating responses from memory CD4+ T cells, the team modeled immune interactions that closely reflect human infection.

Using single-cell sequencing, transcriptional profiling and T cell antigen receptor (TCR) analysis, the researchers characterized the antigen specificity and functional programs associated with effective immune responses.

Recognition of Infected Macrophages as a Key Feature of Protection

The study demonstrates that ~90% of Mtb-specific memory CD4+ T cells from individuals with latent Mtb infection can recognize Mtb-infected macrophages. These cells exhibit a differentiated effector profile and produce key cytokines, including IFNγ, TNF, IL-2, and GM-CSF, consistent with antimicrobial activity. However, it also highlights that T cell recognition is incomplete since up to 10% of CD4+ T cell clonotypes do not efficiently recognize infected macrophages.

Importantly, recognition of infected macrophages by memory T cells represents a functional benchmark for protective immunity. Rather than broadly responding to Mtb-derived peptides, effective T cells must detect and respond to infected macrophages, the context in which bacterial replication occurs.

Convergent Targeting of Virulence-Associated Antigens

A key finding is the convergence of T cell responses on a defined set of virulence-associated antigens. Despite screening responses against more than 90 Mtb proteins, functionally relevant T cells consistently targeted substrates of the mycobacterial type VII secretion system, including CFP10, EspA, and EspC.

These proteins play essential roles in the interaction of Mtb with host phagocytic ells and are critical for bacterial survival. As a result, they are likely to be less susceptible to immune evasion, making them particularly attractive targets for vaccine development. This convergence suggests that effective immunity is not broadly distributed across antigens but instead focused on a limited subset of secreted virulence factors.

A Framework for TB Vaccine Development

By linking antigen specificity, recognition of infected macrophages, and T cell effector programs, the study provides a framework for evaluating vaccine candidates.

These findings may help explain the limited success of previous TB vaccines. While some approaches generated measurable T cell responses, they may not have induced T cells capable of recognizing infected macrophages, a requirement for effective bacterial control.

Moving forward, vaccine strategies can be evaluated not only by the presence of T cell responses, but by their ability to:

• Recognize Mtb-infected macrophages
• Target high-value virulence-associated antigens
• Exhibit appropriate effector functions

Advancing Translational Immunology

The study highlights the importance of models which use human immune cells to understand protective immunity. By using primary human cells under conditions that closely mirror natural infection, the research provides a clinically relevant framework.

Notably, the identified TCR sequences and antigen targets overlap with immune signatures observed in TB-resistant individuals from prior studies in South Africa, suggesting that these responses may represent conserved mechanisms of protection across populations. In addition, the cloned TCRs generated in this work have potential applications in assay development and immune monitoring in clinical trials, or as therapeutics to treat or prevent TB.

Future Directions

Key questions remain, including whether these identified T cell populations directly eliminate bacteria within infected macrophages. Ongoing work will also refine antigen mapping by sequencing and screening many other TCRs linked to recognition of infected macrophages, and further define the peptides presented by macrophages during infection, supported by advances in immunopeptidomics.

Future studies will compare these immune signatures across individuals with latent infection, active disease, and vaccine exposure to determine their correlation with clinical protection. As these findings are extended across patient populations and clinical settings, they have the potential to define the immune signatures of protection bringing the field closer to vaccines capable of controlling one of the world’s most persistent infectious diseases.